Can we achieve ESC 2019 guidelines LDL-cholesterol target in Tunisia?

##plugins.themes.academic_pro.article.sidebar##

Published Feb 11, 2022
Download
pdf
Vol. 100 No. 2 (2022): Issue feb 2022

##plugins.themes.academic_pro.article.main##

Zied Ibn Elhadj
Nour Cherif
Emna Bennour
Saoussen Antit
Widad Echaieb
Lilia Zakhama
Salem Kachboura

Abstract

Introduction: Dyslipidemias are a major cardiovascular risk factor. The control of LDLc level is one of the major targets in patients
admitted for an acute coronary syndrome (ACS).

Aim: To study the lipid profile after ACS and to assess the degree of applicability of the European guidelines in Tunisia.

Methods: This was a prospective, multicentric, non-randomized study involving consecutive patients admitted for ACS between October 2019
and March 2020; for whom a lipid assessment was carried out on admission and checked after four to six weeks under high dose of statin.

Results: One hundred patients were included. The mean age of our population was 58.7 years and the sex ratio was 5.7. Obesity was
present in 15%, Diabetes in 35%, hypertension in 34% and smoking in 61% of cases. Our patients presented with ST segment elevation
myocardial infraction in 51%. The mean total plasma LDLc level was 1.04±0.26g/L. A reduction in LDLc levels of more than 50% was noted
in 33% of patients. A value less than 0.55g/L of LDLc was noted in 46% of patients. The therapeutic target (LDLc<0.55g/L and reduction of
by more than 50%) was achieved in 30% of patients. The only therapeutic alternative was the diet and lifestyle changes.

Conclusion: Our results demonstrate the difficulty of reaching the therapeutic target of LDLc after an ACS in Tunisia. Several factors can
be identified, mainly the absence of therapeutics recommended in second and third line in Tunisia.

##plugins.themes.academic_pro.article.details##

References

  1. Silverman MG, Ference BA, Im K et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA 2016;316:1289-97. DOI: 10.1001/ jama.2016.13985.
  2. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78. DOI: 10.1016/S0140-6736(05)67394-1.
  3. Ueda P, Lung TW-C, Lu Y et al. Treatment gaps and potential cardiovascular risk reduction from expanded statin use in the US and England. PLoS One 2018;13:e0190688. DOI: 10.1371/ journal.pone.0190688.
  4. Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskThe Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 2020;41:111-88. DOI: 10.1093/eurheartj/ehz455.
  5. Kato ET, Cannon CP, Blazing MA et al. Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). J Am Heart Assoc 2017;6. DOI: 10.1161/JAHA.117.006901
  6. Dyrbus K, Gasior M, Desperak P, Nowak J, Osadnik T, Banach M. Characteristics of lipid profile and effectiveness of management of dyslipidaemia in patients with acute coronary syndromes - Data from the TERCET registry with 19,287 patients. Pharmacol. Res. 2019;139:460‑6. DOI: 10.1016/j. phrs.2018.12.002.
  7. Gitt AK, Lautsch D, Ferrières J et al. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II. Atherosclerosis 2017;266:158-66. DOI: 10.1016/j.atherosclerosis.2017.08.013.
  8. Bohula EA, Wiviott SD, Giugliano RP et al. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVEIT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation 2017;136:2440-50. DOI: 10.1161/CIRCULATIONAHA.117.029095.
  9. Nußbaumer B, Glechner A, Kaminski-Hartenthaler A, Mahlknecht P, Gartlehner G. Ezetimibe-Statin Combination Therapy. Dtsch Arztebl Int 2016;113:445-53. DOI: 10.3238/arztebl.2016.0445
  10. Poh K-K, Chin CT, Tong KLet al. Cholesterol goal achievement and lipid-lowering therapy in patients with stable or acute coronary heart disease in Singapore: results from the Dyslipidemia International Study II. Singapore Med J 2019;60:454-62.
  11. Murphy SA, Cannon CP, Blazing MA et al. Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin PostAcute Coronary Syndrome: The IMPROVE-IT Trial. Journal of the American College of Cardiology 2016;67:353-61. DOI: 10.1016/j.jacc.2015.10.077.
  12. Pokharel Y, Chinnakondepalli K, Vilain K et al. Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circ Cardiovasc Qual Outcomes 2017;10. DOI: 10.1161/CIRCOUTCOMES.116.003201.